Center-Authored Papers

Filters: Author is Kublin, James G  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
V
Volk JE, Hessol NA, Gray GE, Kublin JG, Churchyard GJ, Mlisana K, Nchabeleng M, Buchbinder SP, Bekker L-G.  2014.  The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants.. International journal of STD & AIDS. 25(5):332-40. Abstract
P
Pine SO, Kublin JG, Hammer SM, Borgerding J, Huang Y, Casimiro DR, McElrath MJ.  2011.  Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans.. PloS one. 6(4):e18526. Abstract
K
Kublin JG, Mikolajczak SA, Sack BK, Fishbaugher ME, Seilie A, Shelton L, VonGoedert T, Firat M, Magee S, Fritzen E et al..  2017.  Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects.. Science translational medicine. 9(371) Abstract
Kublin JG, Morgan CA, Day TA, Gilbert PB, Self SG, McElrath MJ, Corey L.  2012.  HIV Vaccine Trials Network: activities and achievements of the first decade and beyond.. Clinical investigation. 2(3):245-254. Abstract
Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I et al..  2013.  Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery.. The Journal of infectious diseases. 208(5):818-29. Abstract
H
Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC et al..  2015.  Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.. PloS one. 10(9):e0136626. Abstract
Huang Y, Karuna ST, Janes H, Frahm N, Nason M, Edlefsen PT, Kublin JG, Corey L, McElrath MJ, Gilbert PB.  2015.  Use of placebos in Phase 1 preventive HIV vaccine clinical trials.. Vaccine. 33(6):749-52. Abstract
Huang Y, DiazGranados C, Janes H, Huang Y, Decamp AC, Metch B, Grant S, Sanchez B, Phogat S, Koutsoukos M et al..  2016.  Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.. Current opinion in virology. 17:57-65. Abstract
Hawn TR, Day TA, Scriba TJ, Hatherill M, Hanekom WA, Evans TG, Churchyard GJ, Kublin JG, Bekker L-G, Self SG.  2014.  Tuberculosis vaccines and prevention of infection.. Microbiology and molecular biology reviews : MMBR. 78(4):650-71. Abstract
Hasang WP, Dembo EG, Wijesinghe R, Molyneux ME, Kublin JG, Rogerson S.  2014.  HIV-1 infection and antibodies to Plasmodium falciparum in adults.. The Journal of infectious diseases. Abstract
Hanron AE, Billman ZP, Seilie AM, Olsen TM, Fishbaugher M, Chang M, Rueckle T, Andenmatten N, Greenhouse B, Arinaitwe E et al..  2017.  Multiplex, DNase-free one-step reverse transcription PCR for Plasmodium 18S rRNA and spliced gametocyte-specific mRNAs.. Malaria journal. 16(1):208. Abstract
G
Gray GE, Allen M, Moodie Z, Churchyard G, Bekker L-G, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH et al..  2011.  Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.. The Lancet infectious diseases. 11(7):507-15. Abstract
F
Frahm N, Decamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, Casimiro DR, Duerr A, Robertson MN, Buchbinder SP et al..  2012.  Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.. The Journal of clinical investigation. 122(1):359-67. Abstract
D
Dimitrov D, Kublin JG, Ramsey SD, Corey L.  2015.  Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models. EBioMedicine. 2(12):2062-9. Abstract
Day TA, Kublin JG.  2013.  Lessons learned from HIV vaccine clinical efficacy trials.. Current HIV research. 11(6):441-9. Abstract
Day TA, Morgan CA, Kublin JG.  2013.  Will mosaic vaccine immunogens expand immune response breadth to rival HIV-1 strain diversity? Clinical Investigation. 3(5):413-415.
C
Corey L, McElrath MJ, Kublin JG.  2009.  Post-step modifications for research on HIV vaccines.. AIDS (London, England). 23(1):3-8.
A
Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, Harro C, Keefer MC, Kublin JG, Dubey SA, Kierstead LS et al..  2010.  Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.. The Journal of infectious diseases. 201(1):132-41. Abstract
Artimovich E, Schneider K, Taylor TE, Kublin JG, Dzinjalamala FK, Escalante AA, Plowe CV, Laufer MK, Takala-Harrison S.  2015.  Persistence of Sulfadoxine-Pyrimethamine Resistance Despite Reduction of Drug Pressure in Malawi.. The Journal of infectious diseases. Abstract
Adamson BJS, Carlson JJ, Kublin JG, Garrison LP.  2017.  The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States.. Vaccines. 5(2) Abstract
Adamson BJS, Fuchs JD, Sopher CJ, Flood DM, Johnson PR, Haynes BF, Kublin JG.  2015.  A New Model for Catalyzing Translational Science: The Early Stage Investigator Mentored Research Scholar Program in HIV Vaccines.. Clinical and translational science. 8(2):166-8. Abstract
Abu-Raddad LJ, Barnabas RV, Janes H, Weiss HA, Kublin JG, Longini IM, Wasserheit JN.  2013.  Understanding HIV epidemics: aggregate viral load metrics and 'smoking guns'.. AIDS (London, England). 27(17):2826-7.
Abu-Raddad LJ, Barnabas RV, Janes H, Weiss HA, Kublin JG, Longini IM, Wasserheit JN.  2013.  Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load? AIDS (London, England). 27(15):2494-6.
Abu-Raddad LJ, Barnabas RV, Janes H, Weiss HA, Kublin JG, Longini IM, Wasserheit JN.  2013.  Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load? AIDS (London, England). 27(6):981-89. Abstract